{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:08:45Z","timestamp":1791562125041,"version":"4.3.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03354-y","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:34:43Z","timestamp":1786077283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genomic, transcriptomic, and molecular predictors of response to neoadjuvant therapy in locally advanced rectal cancer: a narrative review"],"prefix":"10.1007","volume":"43","author":[{"given":"Sarah S.","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedrick Kok Hong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"3354_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM-K, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. RAPIDO collaborative investigators, Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(20)30555-6.","journal-title":"Lancet Oncol"},{"key":"3354_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset J-F, Etienne P-L, Rio E, Fran\u00e7ois \u00c9, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouch\u00e9 O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardi\u00e8re C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C. Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group, Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(21)00079-6.","journal-title":"Lancet Oncol"},{"key":"3354_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S1470-2045(25)00542-X","volume":"26","author":"A Amatu","year":"2025","unstructured":"Amatu A, Patelli G, Zampino MG, Bergamo F, Mosconi S, Tosi F, Ciardiello D, Lonardi S, Negrini G, Sibio D, Gerardi MA, Galuppo S, Filippone FR, Carnevali P, Borin S, Pilati P, Poiasina E, Bonazzina E, Gervaso L, Mammano E, Bracco F, Bergamaschi L, Spolverato G, Origi M, Romario UF, Mauri G, Fazio N, Forti E, De Roberto G, Cristofori C, Burti C, Asmundo L, Funicelli L, Ramondo G, Bonaffini PA, Mariano S, Lazzari L, Ghezzi S, Isella C, Cantarella D, Aquilano MC, Bottiglieri L, Bonoldi E, Mutignani M, Torri V, Medico E, Bardelli A, Marsoni S, Vanzulli A, Palazzi MF, Ferrari GC, Bencardino K, Sartore-Bianchi A, Siena S. Total neoadjuvant therapy followed by non-operative management or surgery in stage II-III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025;26:1612\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(25)00542-X.","journal-title":"Lancet Oncol"},{"key":"3354_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00384-025-05009-2","volume":"40","author":"L Lauwereins","year":"2025","unstructured":"Lauwereins L, D\u2019Hoore A, Coeckelberghs E, Fieuws S, Wolthuis A, Bislenghi G, Van Molhem Y, Van Geluwe B, Debrun L, Devoogdt N, De Groef A, Asnong A, Geraerts I. A 2-year prospective study on the evolution of Low Anterior Resection Syndrome (LARS) following rectal cancer surgery. Int J Colorectal Dis. 2025;40:220. https:\/\/doi.org\/10.1007\/s00384-025-05009-2.","journal-title":"Int J Colorectal Dis"},{"key":"3354_CR5","doi-asserted-by":"publisher","unstructured":"Kuhlmann L, Juul T, Emmertsen KJ, Christensen P, Frederiksen NA, Krogsgaard M, Lauritzen MB, Drewes AM. Long-term pain impact after rectal cancer surgery: Trajectories and predictors of patient request for contact from a cohort study. Colorectal Dis. 2025;27. https:\/\/doi.org\/10.1111\/codi.70342.","DOI":"10.1111\/codi.70342"},{"key":"3354_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s13193-024-01991-1","volume":"16","author":"K Chandramohan","year":"2025","unstructured":"Chandramohan K, Mohandas M, Muralee M, Wagh MS, George PS, Geethakumari BS, Mayadevi L. Study of Changes in Quality of Life After Rectal Cancer Surgery Using FACT-C Questionnaire. Indian J Surg Oncol. 2025;16:172\u201381. https:\/\/doi.org\/10.1007\/s13193-024-01991-1.","journal-title":"Indian J Surg Oncol"},{"key":"3354_CR7","doi-asserted-by":"publisher","unstructured":"Zhang H, Cao K, Li G, Zhai Z, Wei G, Qu H, Wang Z, Han J. Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.1049228.","DOI":"10.3389\/fonc.2022.1049228"},{"key":"3354_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/ajco.13877","volume":"19","author":"S Bedrikovetski","year":"2023","unstructured":"Bedrikovetski S, Traeger L, Vather R, Moore JW, Sammour T. Clinical and biochemical predictors of tumor response after neoadjuvant therapy in rectal cancer. Asia Pac J Clin Oncol. 2023;19:365\u201373. https:\/\/doi.org\/10.1111\/ajco.13877.","journal-title":"Asia Pac J Clin Oncol"},{"key":"3354_CR9","doi-asserted-by":"publisher","unstructured":"De Mattia E, Roncato R, Palazzari E, Toffoli G, Cecchin E. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. Front Pharmacol. 2020;11. https:\/\/doi.org\/10.3389\/fphar.2020.00897.","DOI":"10.3389\/fphar.2020.00897"},{"key":"3354_CR10","doi-asserted-by":"publisher","unstructured":"Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy, Cancers (Basel). 13 (2021) 2296. https:\/\/doi.org\/10.3390\/cancers13102296","DOI":"10.3390\/cancers13102296"},{"key":"3354_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s13304-015-0281-8","volume":"67","author":"J Martellucci","year":"2015","unstructured":"Martellucci J, Alemanno G, Castiglione F, Bergamini C, Valeri A. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer. Updates Surg. 2015;67:47\u201353. https:\/\/doi.org\/10.1007\/s13304-015-0281-8.","journal-title":"Updates Surg"},{"key":"3354_CR12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s10350-006-0881-y","volume":"50","author":"H Kobayashi","year":"2007","unstructured":"Kobayashi H, Hashiguchi Y, Ueno H, Shinto E, Kajiwara Y, Mochizuki H. Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy. Dis Colon Rectum. 2007;50:1354\u201362. https:\/\/doi.org\/10.1007\/s10350-006-0881-y.","journal-title":"Dis Colon Rectum"},{"key":"3354_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/jso.26244","volume":"123","author":"P Zhou","year":"2021","unstructured":"Zhou P, Goffredo P, Ginader T, Thompson D, Hrabe J, Gribovskaja-Rupp I, Kapadia M, Hassan I. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer. J Surg Oncol. 2021;123:278\u201385. https:\/\/doi.org\/10.1002\/jso.26244.","journal-title":"J Surg Oncol"},{"key":"3354_CR14","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1245\/s10434-013-2910-0","volume":"20","author":"MP Duldulao","year":"2013","unstructured":"Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, Garcia-Aguilar J. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol. 2013;20:2166\u201371. https:\/\/doi.org\/10.1245\/s10434-013-2910-0.","journal-title":"Ann Surg Oncol"},{"key":"3354_CR15","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/cancers15051469","volume":"15","author":"E De Mattia","year":"2023","unstructured":"De Mattia E, Polesel J, Mezzalira S, Palazzari E, Pollesel S, Toffoli G, Cecchin E. Predictive and Prognostic Value of Oncogene Mutations and Microsatellite Instability in Locally-Advanced Rectal Cancer Treated with Neoadjuvant Radiation-Based Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023;15:1469. https:\/\/doi.org\/10.3390\/cancers15051469.","journal-title":"Cancers (Basel)"},{"key":"3354_CR16","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1245\/s10434-016-5205-4","volume":"23","author":"OS Chow","year":"2016","unstructured":"Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen C-T, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J. KRAS and Combined KRAS\/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Ann Surg Oncol. 2016;23:2548\u201355. https:\/\/doi.org\/10.1245\/s10434-016-5205-4.","journal-title":"Ann Surg Oncol"},{"key":"3354_CR17","doi-asserted-by":"publisher","first-page":"100894","DOI":"10.1016\/j.ctro.2024.100894","volume":"50","author":"K Clasen","year":"2025","unstructured":"Clasen K, Ballin N, Sch\u00fctz L, Bonzheim I, Kelemen O, Orth M, Gani C, Rie\u00df O, Ossowski S, Niyazi M, Schroeder C. Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome. Clin Transl Radiat Oncol. 2025;50:100894. https:\/\/doi.org\/10.1016\/j.ctro.2024.100894.","journal-title":"Clin Transl Radiat Oncol"},{"key":"3354_CR18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ijrobp.2010.06.043","volume":"81","author":"P Erben","year":"2011","unstructured":"Erben P, Str\u00f6bel P, Horisberger K, Popa J, Bohn B, Hanfstein B, K\u00e4hler G, Kienle P, Post S, Wenz F, Hochhaus A, Hofheinz R-D. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2011;81:1032\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.06.043.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3354_CR19","doi-asserted-by":"publisher","first-page":"1716618","DOI":"10.1080\/23723556.2020.1716618","volume":"7","author":"JK Douglas","year":"2020","unstructured":"Douglas JK, Callahan RE, Hothem ZA, Cousineau CS, Kawak S, Thibodeau BJ, Bergeron S, Li W, Peeples CE, Wasvary HJ. Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. Mol Cell Oncol. 2020;7:1716618. https:\/\/doi.org\/10.1080\/23723556.2020.1716618.","journal-title":"Mol Cell Oncol"},{"key":"3354_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12032-018-1202-8","volume":"35","author":"IH Lee","year":"2018","unstructured":"Lee IH, Kang K, Kang BW, Lee SJ, Bae WK, Hwang JE, Kim HJ, Park SY, Park JS, Choi GS, Kim JG. Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Med Oncol. 2018;35:145. https:\/\/doi.org\/10.1007\/s12032-018-1202-8.","journal-title":"Med Oncol"},{"key":"3354_CR21","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/sj.bjc.6602622","volume":"92","author":"E Lopez-Crapez","year":"2005","unstructured":"Lopez-Crapez E, Bibeau F, Th\u00e9zenas S, Ychou M, Simony-Lafontaine J, Thirion A, Azria D, Grenier J, Senesse P. p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis. Br J Cancer. 2005;92:2114\u201321. https:\/\/doi.org\/10.1038\/sj.bjc.6602622.","journal-title":"Br J Cancer"},{"key":"3354_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/DCR.0000000000002245","volume":"66","author":"BC Chapman","year":"2023","unstructured":"Chapman BC, Lai SH, Friedrich T, Lieu CH, Moskalenko M, Olsen JR, Herter W, Birnbaum EH, McCarter MD, Vogel JD. Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy. Dis Colon Rectum. 2023;66:521\u201330. https:\/\/doi.org\/10.1097\/DCR.0000000000002245.","journal-title":"Dis Colon Rectum"},{"key":"3354_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2217\/pgs.10.51","volume":"11","author":"E Balboa","year":"2010","unstructured":"Balboa E, Duran G, Lamas MJ, Gomez-Caama\u00f1o A, Celeiro-Mu\u00f1oz C, Lopez R, Carracedo A, Barros F. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics. 2010;11:747\u201361. https:\/\/doi.org\/10.2217\/pgs.10.51.","journal-title":"Pharmacogenomics"},{"key":"3354_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ijc.34880","volume":"155","author":"K Hammarstr\u00f6m","year":"2024","unstructured":"Hammarstr\u00f6m K, Nunes L, Mathot L, Mezheyeuski A, Lundin E, Korsavidou Hult N, Imam I, Osterlund E, Sj\u00f6blom T, Glimelius B. Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer. Int J Cancer. 2024;155:40\u201353. https:\/\/doi.org\/10.1002\/ijc.34880.","journal-title":"Int J Cancer"},{"key":"3354_CR25","doi-asserted-by":"publisher","unstructured":"London R.E. XRCC1 - Strategies for coordinating and assembling a versatile DNA damage response. DNA Repair (Amst). 2020;93:102917. https:\/\/doi.org\/10.1016\/j.dnarep.2020.102917.","DOI":"10.1016\/j.dnarep.2020.102917"},{"key":"3354_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijrobp.2010.09.053","volume":"82","author":"MJ Lamas","year":"2012","unstructured":"Lamas MJ, Duran G, Gomez A, Balboa E, Anido U, Bernardez B, Rana-Diez P, Lopez R, Carracedo A, Barros F. X-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer Patients. Int J Radiation Oncology*Biology*Physics. 2012;82:138\u201344. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.09.053.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"3354_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.canlet.2008.07.008","volume":"272","author":"J Stoehlmacher","year":"2008","unstructured":"Stoehlmacher J, Goekkurt E, Mogck U, Aust DE, Kramer M, Baretton GB, Liersch T, Ehninger G, Jakob C. Thymidylate synthase genotypes and tumour regression in stage II\/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett. 2008;272:221\u20135. https:\/\/doi.org\/10.1016\/j.canlet.2008.07.008.","journal-title":"Cancer Lett"},{"key":"3354_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/sj.bjc.6605105","volume":"101","author":"M Kikuchi","year":"2009","unstructured":"Kikuchi M, Mikami T, Sato T, Tokuyama W, Araki K, Watanabe M, Saigenji K, Okayasu I. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer. 2009;101:116\u201323. https:\/\/doi.org\/10.1038\/sj.bjc.6605105.","journal-title":"Br J Cancer"},{"key":"3354_CR29","doi-asserted-by":"publisher","unstructured":"Po\u0142omska K, Rybicka M, Ja\u017cd\u017cewska A, Prud M, Jackowska S, Kobiela J, Spychalski P. Single Nucleotide Polymorphisms as Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review. Cancers (Basel). 2025;17. https:\/\/doi.org\/10.3390\/cancers17243995.","DOI":"10.3390\/cancers17243995"},{"key":"3354_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/172460080301800310","volume":"18","author":"G Toffoli","year":"2003","unstructured":"Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, Carbone A. Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. Int J Biol Markers. 2003;18:218\u201321. https:\/\/doi.org\/10.1177\/172460080301800310.","journal-title":"Int J Biol Markers"},{"key":"3354_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3389\/fphar.2020.00897","volume":"11","author":"E De Mattia","year":"2020","unstructured":"De Mattia E, Roncato R, Palazzari E, Toffoli G, Cecchin E. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. Front Pharmacol. 2020;11:897. https:\/\/doi.org\/10.3389\/fphar.2020.00897.","journal-title":"Front Pharmacol"},{"key":"3354_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/tpj.2010.25","volume":"11","author":"E Cecchin","year":"2011","unstructured":"Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R, De Mattia E, Friso ML, Biason P, Visentin M, Nitti D, Toffoli G. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J. 2011;11:214\u201326. https:\/\/doi.org\/10.1038\/tpj.2010.25.","journal-title":"Pharmacogenomics J"},{"key":"3354_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/SLA.0b013e31822b8cfa","volume":"254","author":"J Garcia-Aguilar","year":"2011","unstructured":"Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, Marcet J, Pastor C. Identification of a Biomarker Profile Associated With Resistance to Neoadjuvant Chemoradiation Therapy in Rectal Cancer. Ann Surg. 2011;254:486\u201393. https:\/\/doi.org\/10.1097\/SLA.0b013e31822b8cfa.","journal-title":"Ann Surg"},{"key":"3354_CR34","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/01.fpc.0000230412.89973.c0","volume":"16","author":"S Terrazzino","year":"2006","unstructured":"Terrazzino S, Agostini M, Pucciarelli S, Pasetto LM, Friso ML, Ambrosi A, Lisi V, Leon A, Lise M, Nitti D. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics. 2006;16:817\u201324. https:\/\/doi.org\/10.1097\/01.fpc.0000230412.89973.c0.","journal-title":"Pharmacogenet Genomics"},{"key":"3354_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/tpj.2010.62","volume":"11","author":"A Ho-Pun-Cheung","year":"2011","unstructured":"Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, Bibeau F, Boissi\u00e8re-Michot F, Thezenas S, Cellier D, Azria D, Rouanet P, Senesse P, Ychou M, Lopez-Crapez E. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Pharmacogenomics J. 2011;11:437\u201343. https:\/\/doi.org\/10.1038\/tpj.2010.62.","journal-title":"Pharmacogenomics J"},{"key":"3354_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.21873\/anticanres.11319","volume":"37","author":"MD Santos","year":"2017","unstructured":"Santos MD, Silva C, Rocha A, Nogueira C, Castro-Po\u00e7as F, Araujo A, Matos E, Pereira C, Medeiros R, Lopes C. Prognostic and Therapeutic Potential Implications of Genetic Variability in Prostaglandin E2 Pathway Genes in Rectal Cancer. Anticancer Res. 2017;37:281\u201391. https:\/\/doi.org\/10.21873\/anticanres.11319.","journal-title":"Anticancer Res"},{"key":"3354_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/codi.12395","volume":"16","author":"GA Gantt","year":"2014","unstructured":"Gantt GA, Chen Y, Dejulius K, Mace AG, Barnholtz-Sloan J, Kalady MF. Gene expression profile is associated with chemoradiation resistance in rectal cancer. Colorectal Dis. 2014;16:57\u201366. https:\/\/doi.org\/10.1111\/codi.12395.","journal-title":"Colorectal Dis"},{"key":"3354_CR38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s00595-011-0027-2","volume":"42","author":"S Saigusa","year":"2012","unstructured":"Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Fujikawa H, Matsushita K, Uchida K, Inoue Y, Kusunoki M. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today. 2012;42:460\u20139. https:\/\/doi.org\/10.1007\/s00595-011-0027-2.","journal-title":"Surg Today"},{"key":"3354_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12014-018-9192-2","volume":"15","author":"A Chauvin","year":"2018","unstructured":"Chauvin A, Wang C-S, Geha S, Garde-Granger P, Mathieu A-A, Lacasse V, Boisvert F-M. The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature. Clin Proteom. 2018;15:16. https:\/\/doi.org\/10.1186\/s12014-018-9192-2.","journal-title":"Clin Proteom"},{"key":"3354_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/his.13227","volume":"71","author":"H Takahashi","year":"2017","unstructured":"Takahashi H, Nakamura K, Usami A, Tsuruta T, Hashimura M, Matsumoto T, Saegusa M. Possible role of nuclear \u03b2-catenin in resistance to preoperative chemoradiotherapy in locally advanced rectal cancer. Histopathology. 2017;71:227\u201337. https:\/\/doi.org\/10.1111\/his.13227.","journal-title":"Histopathology"},{"key":"3354_CR41","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41591-022-01930-z","volume":"28","author":"WK Chatila","year":"2022","unstructured":"Chatila WK, Kim JK, Walch H, Marco MR, Chen C-T, Wu F, Omer DM, Khalil DN, Ganesh K, Qu X, Luthra A, Choi S-H, Ho Y-J, Kundra R, Groves KI, Chow OS, Cercek A, Weiser MR, Widmar M, Wei IH, Pappou EP, Nash GM, Paty PB, Shi Q, Vakiani E, Duygu S, Selcuklu MTA, Donoghue DB, Solit MF, Berger J, Shia R, Pelossof PB, Romesser R, Yaeger JJ, Smith N, Schultz F, Sanchez-Vega J. Garcia-Aguilar, Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat Med. 2022;28:1646\u201355. https:\/\/doi.org\/10.1038\/s41591-022-01930-z.","journal-title":"Nat Med"},{"key":"3354_CR42","doi-asserted-by":"publisher","first-page":"154158","DOI":"10.1016\/j.prp.2022.154158","volume":"239","author":"H-P Chen","year":"2022","unstructured":"Chen H-P, Chen C-I, Liu K-W, Chen T-J, Tian Y-F, Kuo Y-H, Li W-S, Tsai H-H, Wu L-C, Yeh C-F, Li C-F, Chou C-L, Lai H-Y. High SLC28A2 expression endows an inferior survival for rectal cancer patients managed by neoadjuvant CCRT. Pathol Res Pract. 2022;239:154158. https:\/\/doi.org\/10.1016\/j.prp.2022.154158.","journal-title":"Pathol Res Pract"},{"key":"3354_CR43","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41416-022-01842-2","volume":"127","author":"G Emons","year":"2022","unstructured":"Emons G, Auslander N, Jo P, Kitz J, Azizian A, Hu Y, Hess CF, Roedel C, Sax U, Salinas G, Stroebel P, Kramer F, Beissbarth T, Grade M, Ghadimi M, Ruppin E, Ried T, Gaedcke J. Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy. Br J Cancer. 2022;127:766\u201375. https:\/\/doi.org\/10.1038\/s41416-022-01842-2.","journal-title":"Br J Cancer"},{"key":"3354_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cancergen.2015.03.010","volume":"208","author":"C Lopes-Ramos","year":"2015","unstructured":"Lopes-Ramos C, Koyama FC, Habr-Gama A, Salim ACM, Bettoni F, Asprino PF, Fran\u00e7a GS, Gama-Rodrigues J, Parmigiani RB, Perez RO, Galante PAF, Camargo AA. Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer. Cancer Genet. 2015;208:319\u201326. https:\/\/doi.org\/10.1016\/j.cancergen.2015.03.010.","journal-title":"Cancer Genet"},{"key":"3354_CR45","doi-asserted-by":"publisher","first-page":"e2252140","DOI":"10.1001\/jamanetworkopen.2022.52140","volume":"6","author":"T Akiyoshi","year":"2023","unstructured":"Akiyoshi T, Wang Z, Kaneyasu T, Gotoh O, Tanaka N, Amino S, Yamamoto N, Kawachi H, Mukai T, Hiyoshi Y, Nagasaki T, Yamaguchi T, Konishi T, Fukunaga Y, Noda T, Mori S. Transcriptomic Analyses of Pretreatment Tumor Biopsy Samples, Response to Neoadjuvant Chemoradiotherapy, and Survival in Patients With Advanced Rectal Cancer., JAMA Netw. Open. 2023;6:e2252140. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.52140.","journal-title":"Open"},{"key":"3354_CR46","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/SLA.0000000000003051","volume":"271","author":"S Hasan","year":"2020","unstructured":"Hasan S, Renz P, Wegner RE, Finley G, Raj M, Monga D, McCormick J, Kirichenko A. Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer: A National Cancer Database (NCDB) Analysis. Ann Surg. 2020;271:716\u201323. https:\/\/doi.org\/10.1097\/SLA.0000000000003051.","journal-title":"Ann Surg"},{"key":"3354_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13304-019-00697-2","volume":"72","author":"T Acar","year":"2020","unstructured":"Acar T, Acar N, Kamer E, Tekindal MA, Cengiz F, Kar H, Atahan K, Haciyanli M. Do microsatellite instability (MSI) and deficient mismatch repair (dMMR) affect the pathologic complete response (pCR) in patients with rectal cancer who received neoadjuvant treatment? Updates Surg. 2020;72:73\u201382. https:\/\/doi.org\/10.1007\/s13304-019-00697-2.","journal-title":"Updates Surg"},{"key":"3354_CR48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/jso.26771","volume":"125","author":"K Ni","year":"2022","unstructured":"Ni K, Zhan Y, Liu Z, Zhao X-Z, Wang W, Wang G, Zhang Z, Li G, Zhang X, Zhang C. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients. J Surg Oncol. 2022;125:692\u2013702. https:\/\/doi.org\/10.1002\/jso.26771.","journal-title":"J Surg Oncol"},{"key":"3354_CR49","doi-asserted-by":"publisher","first-page":"153303382312028","DOI":"10.1177\/15330338231202893","volume":"22","author":"S Qing","year":"2023","unstructured":"Qing S, Gu L, Du T, Yin X, Zhang K-J, Zhang H-J. A Predictive Model to Evaluate Pathologic Complete Response in Rectal Adenocarcinoma., Technol. Cancer Res Treat. 2023;22:15330338231202892. https:\/\/doi.org\/10.1177\/15330338231202893.","journal-title":"Cancer Res Treat"},{"key":"3354_CR50","doi-asserted-by":"publisher","first-page":"107327482312149","DOI":"10.1177\/10732748231214936","volume":"30","author":"S Shi","year":"2023","unstructured":"Shi S, Zhou M, Wang G, Xu J, Zhang D, Zheng M, Zhang S. Cytokeratin 7 Expression and Mismatch Repair Status for Survival Prediction in Patients With Low Rectal Cancer After Neoadjuvant Therapy. Cancer Control. 2023;30:10732748231214936. https:\/\/doi.org\/10.1177\/10732748231214936.","journal-title":"Cancer Control"},{"key":"3354_CR51","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.clcc.2025.09.001","volume":"24","author":"JA Nieuwstraten","year":"2025","unstructured":"Nieuwstraten JA, van Geffen EGM, Leenders MWH, Tanis PJ, Kusters M, Aukema TS. Incidence of Mismatch Repair Deficiency in Rectal Cancer and Response to Neoadjuvant Treatment., Clin. Colorectal Cancer. 2025;24:483\u201391. https:\/\/doi.org\/10.1016\/j.clcc.2025.09.001.","journal-title":"Colorectal Cancer"},{"key":"3354_CR52","doi-asserted-by":"publisher","first-page":"35233","DOI":"10.18632\/oncotarget.9125","volume":"7","author":"H Peng","year":"2016","unstructured":"Peng H, You K, Zhang R, Xi S, Zhang T, Dong J, Cai M, Wang C, Zhang H, Zhou T, Gao Y, Wen B. Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma. Oncotarget. 2016;7:35233\u201340. https:\/\/doi.org\/10.18632\/oncotarget.9125.","journal-title":"Oncotarget"},{"key":"3354_CR53","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12032-011-9819-x","volume":"29","author":"H Yan","year":"2012","unstructured":"Yan H, Yu J, Wang R, Jiang S, Zhu K, Mu D, Xu Z. Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy. Med Oncol. 2012;29:168\u201373. https:\/\/doi.org\/10.1007\/s12032-011-9819-x.","journal-title":"Med Oncol"},{"key":"3354_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/CAD.0b013e32832b53ff","volume":"20","author":"K Horisberger","year":"2009","unstructured":"Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, Wenz F, Hochhaus A, Post S, Willeke F, Hofheinz R-D. MARGIT (Mannheimer Arbeitsgruppe f\u00fcr Gastrointestinale Tumoren), Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs. 2009;20:519\u201324. https:\/\/doi.org\/10.1097\/CAD.0b013e32832b53ff.","journal-title":"Anticancer Drugs"},{"key":"3354_CR55","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00384-012-1542-3","volume":"28","author":"BY Shim","year":"2013","unstructured":"Shim BY, Jung J-H, Lee K-M, Kim H-J, Hong SH, Kim SH, Sun DS, Cho H-M. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer. Int J Colorectal Dis. 2013;28:375\u201383. https:\/\/doi.org\/10.1007\/s00384-012-1542-3.","journal-title":"Int J Colorectal Dis"},{"key":"3354_CR56","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3892\/or_00000491","volume":"22","author":"H Yasuda","year":"2009","unstructured":"Yasuda H, Tanaka K, Saigusa S, Toiyama Y, Koike Y, Okugawa Y, Yokoe T, Kawamoto A, Inoue Y, Miki C, Kusunoki M. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep. 2009;22:709\u201317. https:\/\/doi.org\/10.3892\/or_00000491.","journal-title":"Oncol Rep"},{"key":"3354_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/PPO.0b013e3181629a67","volume":"14","author":"J Peng","year":"2008","unstructured":"Peng J, Lu JJ, Zhu J, Xu Y, Lu H, Lian P, Cai G, Cai S. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer. Cancer J. 2008;14:54\u201361. https:\/\/doi.org\/10.1097\/PPO.0b013e3181629a67.","journal-title":"Cancer J"},{"key":"3354_CR58","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1245\/s10434-012-2394-3","volume":"19","author":"S-W Jao","year":"2012","unstructured":"Jao S-W, Chen S-F, Lin Y-S, Chang Y-C, Lee T-Y, Wu C-C, Jin J-S, Nieh S. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol. 2012;19:3432\u201340. https:\/\/doi.org\/10.1245\/s10434-012-2394-3.","journal-title":"Ann Surg Oncol"},{"key":"3354_CR59","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/jcmm.12879","volume":"20","author":"T G\u00f3mez","year":"2016","unstructured":"G\u00f3mez T, Del Pulgar A, Cebri\u00e1n MJ, Fern\u00e1ndez-Ace\u00f1ero A, Borrero-Palacios L, Del Puerto-Nevado J, Mart\u00ednez-Useros JP, Mar\u00edn-Arango C, Caram\u00e9s R, Vega-Bravo M, Rodr\u00edguez-Rem\u00edrez M, Cruz-Ramos F, Manzarbeitia J. Garc\u00eda-Foncillas, Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. J Cell Mol Med. 2016;20:1729\u201336. https:\/\/doi.org\/10.1111\/jcmm.12879.","journal-title":"J Cell Mol Med"},{"key":"3354_CR60","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1002\/bjs.10695","volume":"105","author":"FC Koyama","year":"2018","unstructured":"Koyama FC, Lopes Ramos CM, Ledesma F, Alves VAF, Fernandes JM, Vailati BB, S\u00e3o Juli\u00e3o GP, Habr-Gama A, Gama-Rodrigues J, Perez RO, Camargo AA. Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer. Br J Surg. 2018;105:e192\u2013203. https:\/\/doi.org\/10.1002\/bjs.10695.","journal-title":"Br J Surg"},{"key":"3354_CR61","doi-asserted-by":"publisher","first-page":"68328","DOI":"10.18632\/oncotarget.12008","volume":"7","author":"K Zhu","year":"2016","unstructured":"Zhu K, Zhao Q, Yue J, Shi P, Yan H, Xu X, Wang R. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer. Oncotarget. 2016;7:68328\u201338. https:\/\/doi.org\/10.18632\/oncotarget.12008.","journal-title":"Oncotarget"},{"key":"3354_CR62","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12885-018-4048-8","volume":"18","author":"J Martinez-Useros","year":"2018","unstructured":"Martinez-Useros J, Moreno I, Fernandez-Ace\u00f1ero MJ, Rodriguez-Remirez M, Borrero-Palacios A, Cebrian A, Del Pulgar TG, Del Puerto-Nevado L, Li W, Puime-Otin A, Perez N, Soengas MS, Garcia-Foncillas J. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer. BMC Cancer. 2018;18:144. https:\/\/doi.org\/10.1186\/s12885-018-4048-8.","journal-title":"BMC Cancer"},{"key":"3354_CR63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12935-022-02530-0","volume":"22","author":"J Wang","year":"2022","unstructured":"Wang J, Liu J, Wang J, Wang S, Li F, Li R, Liu P, Li M, Wang C. Identification of proteomic markers for prediction of the response to 5-Fluorouracil based neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Cancer Cell Int. 2022;22:117. https:\/\/doi.org\/10.1186\/s12935-022-02530-0.","journal-title":"Cancer Cell Int"},{"key":"3354_CR64","doi-asserted-by":"publisher","unstructured":"Stanojevic A, Samiotaki M, Lygirou V, Marinkovic M, Nikolic V, Stojanovic-Rundic S, Jankovic R, Vlahou A, Panayotou G, Fijneman RJA, Castellv\u00ed-Bel S, Zoidakis J, Cavic M. Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms242015412.","DOI":"10.3390\/ijms242015412"},{"key":"3354_CR65","doi-asserted-by":"publisher","unstructured":"Caram\u00e9s C, Cristobal I, Moreno V, Mar\u00edn JP, Gonz\u00e1lez-Alonso P, Torrej\u00f3n B, Minguez P, Leon A, Mart\u00edn JI, Hern\u00e1ndez R, Pedregal M, Mart\u00edn MJ, Cort\u00e9s D, Garc\u00eda-Olmo D, Fern\u00e1ndez MJ, Rojo F. Garc\u00eda-Foncillas, MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer. Int J Mol Sci. 2016;17. https:\/\/doi.org\/10.3390\/ijms17060878.","DOI":"10.3390\/ijms17060878"},{"key":"3354_CR66","doi-asserted-by":"publisher","first-page":"e0206542","DOI":"10.1371\/journal.pone.0206542","volume":"13","author":"M Campayo","year":"2018","unstructured":"Campayo M, Navarro A, Ben\u00edtez JC, Santasusagna S, Ferrer C, Monz\u00f3 M, Cirera L. miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer. PLoS ONE. 2018;13:e0206542. https:\/\/doi.org\/10.1371\/journal.pone.0206542.","journal-title":"PLoS ONE"},{"key":"3354_CR67","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00384-012-1549-9","volume":"28","author":"EAH Kheirelseid","year":"2013","unstructured":"Kheirelseid EAH, Miller N, Chang KH, Curran C, Hennessey E, Sheehan M, Newell J, Lemetre C, Balls G, Kerin MJ. miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis. 2013;28:247\u201360. https:\/\/doi.org\/10.1007\/s00384-012-1549-9.","journal-title":"Int J Colorectal Dis"},{"key":"3354_CR68","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3892\/mmr.2018.9215","volume":"18","author":"B Du","year":"2018","unstructured":"Du B, Wang X, Wu D, Wang T, Yang X, Wang J, Shi X, Chen L, Zhang W. MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer. Mol Med Rep. 2018;18:1909\u201316. https:\/\/doi.org\/10.3892\/mmr.2018.9215.","journal-title":"Mol Med Rep"},{"key":"3354_CR69","doi-asserted-by":"publisher","first-page":"249","DOI":"10.21873\/cgp.20185","volume":"17","author":"T Machackova","year":"2020","unstructured":"Machackova T, Trachtova K, Prochazka V, Grolich T, Farkasova M, Fiala L, Sefr R, Kiss I, Skrovina M, Dosoudil M, Berindan-Neagoe I, Svoboda M, Slaby O, Kala Z. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy. Cancer Genomics Proteom. 2020;17:249\u201357. https:\/\/doi.org\/10.21873\/cgp.20185.","journal-title":"Cancer Genomics Proteom"},{"key":"3354_CR70","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/bjc.2017.492","volume":"118","author":"E Rampazzo","year":"2018","unstructured":"Rampazzo E, Del Bianco P, Bertorelle R, Boso C, Perin A, Spiro G, Bergamo F, Belluco C, Buonadonna A, Palazzari E, Lonardi S, De Paoli A, Pucciarelli S, De Rossi A. The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. Br J Cancer. 2018;118:878\u201386. https:\/\/doi.org\/10.1038\/bjc.2017.492.","journal-title":"Br J Cancer"},{"key":"3354_CR71","doi-asserted-by":"publisher","first-page":"100667","DOI":"10.1016\/j.ctro.2023.100667","volume":"42","author":"GL Jensen","year":"2023","unstructured":"Jensen GL, Pourfarrokh N, Volz M, Morales LL, Walker K, Hammonds KP, El-Ghamry M, Wong L, Hodjat P, Castro E, Rao A, Jhavar SG. Improved Pathologic response to chemoradiation in MGMT methylated locally advanced rectal cancer. Clin Transl Radiat Oncol. 2023;42:100667. https:\/\/doi.org\/10.1016\/j.ctro.2023.100667.","journal-title":"Clin Transl Radiat Oncol"},{"key":"3354_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/COC.0000000000000609","volume":"43","author":"AL Appelt","year":"2020","unstructured":"Appelt AL, Andersen RF, Lindebjerg J, Jakobsen A. Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Secondary Analysis of a Randomized Trial. Am J Clin Oncol. 2020;43:9\u201313. https:\/\/doi.org\/10.1097\/COC.0000000000000609.","journal-title":"Am J Clin Oncol"},{"key":"3354_CR73","doi-asserted-by":"publisher","unstructured":"M\u00f6gele T, H\u00f6ck M, Sommer F, Friedrich L, Sommer S, Schmutz M, Altenburger A, Messmann H, Anthuber M, Kr\u00f6ncke T, St\u00fcben G, Trepel M, M\u00e4rkl B, Dintner S, Claus R. Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial). Cancers (Basel). 2024;16. https:\/\/doi.org\/10.3390\/cancers16244173.","DOI":"10.3390\/cancers16244173"},{"key":"3354_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctro.2022.06.002","volume":"36","author":"CG Truelsen","year":"2022","unstructured":"Truelsen CG, Kronborg CS, S\u00f8rensen BS, Callesen LB, Spindler K-LG. Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy. Clin Transl Radiat Oncol. 2022;36:9\u201315. https:\/\/doi.org\/10.1016\/j.ctro.2022.06.002.","journal-title":"Clin Transl Radiat Oncol"},{"key":"3354_CR75","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/1078-0432.CCR-20-2299","volume":"27","author":"J Zhou","year":"2021","unstructured":"Zhou J, Wang C, Lin G, Xiao Y, Jia W, Xiao G, Liu Q, Wu B, Wu A, Qiu H, Zhang F, Hu K, Xue H, Shen Z, Wang Z, Han J, Niu B, Xu Y, Yu Z, Yang L. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study., Clin. Cancer Res. 2021;27:301\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2299.","journal-title":"Cancer Res"},{"key":"3354_CR76","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-25-1242","volume":"31","author":"T Akiyoshi","year":"2025","unstructured":"Akiyoshi T, Shinozaki E, Maeda Y, Taguchi S, Chino A, Hanaoka Y, Toda S, Matoba S, Tin A, Spickard E, Tominaga T, Shigeta K, Okabayashi K, Matsui S, Mukai T, Yamaguchi T, Osumi H, Jurdi A, Liu MC, Miyazaki N, Yamaguchi K. ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial., Clin. Cancer Res. 2025;31:5188\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1242.","journal-title":"Cancer Res"},{"key":"3354_CR77","doi-asserted-by":"publisher","unstructured":"Troncarelli Flores BC, Souza V, Silva E, Ali Abdallah E, Mello CAL, Gobo Silva ML, Gomes Mendes G, Camila Braun A, Aguiar Junior S. Thom\u00e9 Domingos Chinen, Molecular and Kinetic Analyses of Circulating Tumor Cells as Predictive Markers of Treatment Response in Locally Advanced Rectal Cancer Patients. Cells. 2019;8. https:\/\/doi.org\/10.3390\/cells8070641.","DOI":"10.3390\/cells8070641"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03354-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03354-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03354-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:20:34Z","timestamp":1788924034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03354-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":77,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3354"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03354-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"237"}}